JDRF Statement on FDA Advisory Committee Recommendation of Teplizumab

JDRF applauds the U.S. Food and Drug Administration’s (FDA) Advisory Committee positive recommendation in support of approval of teplizumab for those at risk for developing clinical T1D. We thank the committee for their thorough and considerate review of the evidence and future impact of teplizumab. If approved, this will be the first disease-modifying drug for individuals at-risk for developing clinical T1D, and thus, today is a major milestone for our community and our mission to accelerate life-changing breakthroughs. Disease modifying therapies put us on the critical pathway to preventing and ultimately curing T1D.